share_log

Bristol-Myers Squibb | DEFA14A: Others

Bristol-Myers Squibb | DEFA14A: Others

施贵宝 | DEFA14A:其他
美股sec公告 ·  03/28 22:39
Moomoo AI 已提取核心信息
Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are intended for further communication with the company's shareholders in relation to the proxy solicitation. The company has confirmed that no filing fee is required for this submission. The nature of the additional materials has not been specified in the announcement.
Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are intended for further communication with the company's shareholders in relation to the proxy solicitation. The company has confirmed that no filing fee is required for this submission. The nature of the additional materials has not been specified in the announcement.
领先的制药公司百时美施贵宝已向美国证券交易委员会(SEC)提交了明确的补充材料,作为其委托书的一部分。根据1934年《证券交易法》第14(a)条,该文件表明,这些材料旨在与公司股东就代理招标进行进一步沟通。该公司已确认本次提交不需要任何申请费。公告中未具体说明额外材料的性质。
领先的制药公司百时美施贵宝已向美国证券交易委员会(SEC)提交了明确的补充材料,作为其委托书的一部分。根据1934年《证券交易法》第14(a)条,该文件表明,这些材料旨在与公司股东就代理招标进行进一步沟通。该公司已确认本次提交不需要任何申请费。公告中未具体说明额外材料的性质。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息